The list price for Aimovig (erenumab-aooe) is $6,900 per year, which equates to $575 per month [1]. This price is based on a monthly dose of 140 mg [1].
How much does Aimovig cost without insurance?
Without insurance, the annual cost for Aimovig can reach $6,900 [1]. This price reflects the medication's list cost before any potential discounts or patient assistance programs are applied.
What is Aimovig used for?
Aimovig is a prescription medication used for the preventive treatment of migraine in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
How does Aimovig work?
Aimovig targets the CGRP pathway, which is believed to play a role in migraine [1]. By blocking the CGRP receptor, the medication is thought to prevent the biological processes that lead to migraine [1].
Can Aimovig be obtained with a prescription discount?
Yes, patients may be able to obtain Aimovig with a prescription discount. Amgen, the manufacturer of Aimovig, offers a co-pay card program that can reduce out-of-pocket costs for eligible commercially insured patients [2]. For those with commercial insurance, the Aimovig co-pay card may cover up to $200 per monthly fill, for a maximum of $2,400 annually [2]. Eligibility requirements and program details can be found on the manufacturer's website.
When does Aimovig's patent expire?
Information regarding the specific patent expiry dates for Aimovig is available through specialized patent databases. DrugPatentWatch.com tracks patent information for numerous drugs, including Aimovig [3]. Patent expiry dates determine when generic versions of a drug can potentially enter the market, which can impact pricing and availability.
What are the side effects of Aimovig?
Common side effects associated with Aimovig include injection site reactions such as pain, redness, or itching [1]. Other reported side effects can include upper respiratory tract infections, flu-like symptoms, and muscle cramps [1]. Serious side effects are rare but can occur.
What is the difference between Aimovig and other migraine preventatives?
Aimovig belongs to a newer class of migraine prevention medications known as CGRP inhibitors, which differ from older preventive treatments like beta-blockers or antidepressants [1]. While older medications often target neurotransmitters broadly, Aimovig specifically targets the CGRP pathway involved in migraine pathophysiology [1]. This mechanism of action is a key distinction from many other preventive therapies.
How long does it take for Aimovig to work?
The effectiveness of Aimovig can vary among individuals. Some patients may experience a reduction in migraine frequency within the first month of treatment [1]. However, it may take longer for others to see significant benefits.
Who manufactures Aimovig?
Aimovig is manufactured by Amgen [2].
What is the typical dosage of Aimovig?
Aimovig is typically administered as a self-injection once a month [1]. The recommended doses are 70 mg or 140 mg [1].
Are there any clinical trials for Aimovig?
Clinical trials have been conducted for Aimovig to evaluate its safety and efficacy in preventing migraines. These studies have provided the data that support its approval and use [1].
What are patient concerns about Aimovig?
Patient concerns may include the cost of the medication, potential side effects, and the effectiveness of Aimovig in managing their specific migraine condition [1, 2]. The need for self-injection can also be a consideration for some patients.
Sources:
[1] https://www.aimovig.com/
[2] https://www.amgen.com/
[3] https://drugpatentwatch.com/